Moderna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.
Follow MRNA
Moderna, Inc. (MRNA) Return on invested capital
Moderna, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −93.5%, down 38.0 percentage points from fiscal 2025 (−55.5%). Over the past ten years it has ranged from −626.6% (fiscal 2018) to 206.9% (fiscal 2021); the current reading is higher than 40% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −55.5% | 7.47 |
| FY2024 | −63.0% | (17.50) |
| FY2023 | −45.5% | (103.58) |
| FY2022 | 58.1% | (148.77) |
| FY2021 | 206.9% | 206.87 |
| FY2020 | 0.00% | 311.74 |
| FY2019 | −311.7% | 314.89 |
| FY2018 | −626.6% | (626.63) |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 60.2% |
| VRTX Vertex Pharmaceuticals Incorporated compare | 24.1% |
| ARGX argenex SE compare | 20.7% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 9.34% |
| RPRX Royalty Pharma PLC compare | 5.28% |
| RVMD Revolution Medicines, Inc. compare | 0.00% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −34.5% |
| MRNA Moderna, Inc. | −93.5% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on MRNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement